Biologics

Vivex Biologics launched its Via Mend synthetic bone fillers, a line of bone graft substitutes, the company announced July 15.

Since launching its initial public offering in February, orthobiologics company Bioventus marked several notable achievements, including a multimillion-dollar acquisition.

Durham, N.C.-based Bioventus has launched a new allograft substitute product, Osteoamp Select Flowable, the company said July 13.

Orthopedic device company RTI Surgical partnered with Exactech to develop and supply biologic bone grafts.

Orthopedic surgeon Scott Rodeo, MD, of New York City-based Hospital for Special Surgery received a $50,000 grant from the Orthopaedic Research and Education Foundation to study an injectable knee biologic.

Lawsuits on behalf of a Florida woman and a Delaware man were filed against Aziyo Biologics after they received a tainted FiberCel implant.

Orthopedic device company Arthrex struck a deal with Celularity to distribute biomaterial products for orthopedic surgery, according to a July 1 news release.

The number of patients treated for tuberculosis after undergoing spine surgery with FiberCel, a bone matrix allograft, is growing.

Ortho Regenerative Technologies named Howard Walthall and Tim Cunningham to its board of directors, the company said June 15.

The FDA is ramping up enforcement activities against companies developing unapproved stem cell therapies, particularly for spine and orthopedic indications, according to the Regulatory Affairs Professional Society.